Associations between Lyme disease and certain neurodegenerative diseases have been proposed, but supportive evidence for an association is lacking. Similar geographic distributions would be expected if two conditions were etiologically linked. The absence of a positive correlation between the geographic distribution of Lyme disease and the distribution of deaths due to Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson disease provides further evidence that Lyme disease is not associated with the development of these neurodegenerative conditions.
Lyme disease is a complex, multisystem tickborne illness caused by the spirochete Borrelia burgdorferi. Each year in the United States, >30,000 cases are reported, but the actual number of infections may be 10-fold higher. Lyme disease cases are most commonly reported from the Northeast, mid-Atlantic, and upper Midwest regions of the United States. Central nervous system infection resulting in early neurologic Lyme disease, and more rarely late neurologic Lyme disease, is well documented.
Because of the neurotropism of Lyme disease, speculative websites and articles and even peer-reviewed journals have purported causal associations between Lyme disease and several neurodegenerative disorders, including Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson disease. Researchers have critically evaluated these proposed biologic associations between Lyme disease and Alzheimer disease, ALS, MS, and Parkinson disease, but none have found evidence of an association. It was hypothesized that, if there is a link between B. burgdorferi infection and subsequent development of Alzheimer disease, ALS, MS, or Parkinson disease, the geographic distribution of these neurodegenerative disorders should correlate with that of Lyme disease.
To determine if such a correlation exists, researchers compared the distribution of confirmed cases of Lyme disease in the United States with the distribution of deaths due to these four neurodegenerative disorders. They compared Lyme disease incidence rates in each state with death rates for Alzheimer disease, ALS, MS, and Parkinson disease. Reports of confirmed Lyme disease cases submitted to the National Notifiable Diseases Surveillance System during 2001 to 2010 were used to calculate state-specific, age-adjusted incidence rates of Lyme disease. Age-adjusted death rates of Alzheimer disease, ALS, MS, and Parkinson disease during the same time period were obtained from the CDC WONDER (Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research) database.
During 2001 to 2010, a total of 256,373 confirmed Lyme disease cases were reported in the United States. The median age of patients was 42 years; 137,377 (55%) patients were male. As expected, Lyme disease cases were concentrated in the Northeast, mid-Atlantic, and upper Midwest. Standardized state-specific Lyme disease incidence rates ranged from <1 case per 100,000 person-years for 34 states to 19–73 cases per 100,000 person years for 13 high-incidence states in the Northeast, mid-Atlantic, and upper Midwest (overall median incidence 0.4 cases/100,000 person-years).
During the study period, 705,735 deaths were attributed to Alzheimer disease (median patient age 86 y, 29% male), 59,769 to ALS (median patient age 69 y, 54% male), 34,298 to MS (median patient age 60 y, 34% male), and 190,428 to Parkinson disease (median patient age 82 y, 58% male). Overall, disease-specific, age-adjusted median death rates ranged from a low of 1.1 deaths per 100,000 person-years for MS (range across states 0.2–2.1) to a high of 24.5 deaths per 100,000 person years for Alzheimer disease (range across states 9.6–41.2).
Lyme disease incidence per state was not correlated with rates of death due to ALS (rs = 0.19, p = 0.19), MS (rs = 0.20, p = 0.17), or Parkinson disease (rs = −0.14, p = 0.34). An inverse correlation was detected between Lyme disease and Alzheimer disease (rs = −0.35, p = 0.01). Findings were similar when evaluated with Pearson correlation coefficients, when sub-analysis by sex was performed, and when analysis was limited to states with >1 Lyme disease case per 100,000 person-years.
As with other vector-borne diseases, Lyme disease is highly focal in its geographic distribution. If Lyme disease was etiologically linked to Alzheimer disease, ALS, MS, or Parkinson disease, rates of death attributed to these diseases would be expected to correlate geographically with the geographic incidence of Lyme disease. The findings show, on a coarse geographic scale, no correlation between Lyme disease and these neurodegenerative conditions. The inverse correlation between the rates of Lyme disease and death from Alzheimer disease is in line with findings from a previous report; although this finding is of unclear significance, it supports a lack of positive correlation between these conditions.
Positive spatial clustering was demonstrated for each disease. This finding indicates that for each disease, states with high rates are nearer than would be randomly expected to other states that also have high rates of the disease. However, the researchers showed that the clustering of rates of death from the four neurodegenerative conditions does not correlate with state-specific Lyme disease incidence, indicating that underlying processes that contribute to geographic clustering of neurodegenerative conditions are unrelated to Lyme disease. Each of the diseases, including Lyme disease, has a unique and nonrandom geographic distribution; the distributions of the neurodegenerative disorders do not mirror that of Lyme disease.
As for ALS and Parkinson disease, Lyme disease patients are more commonly male; MS and Alzheimer disease patients are more commonly female. It is conceivable that variations between states in sex distribution of the population could contribute to the lack of observed correlation between Lyme disease and the four neurodegenerative disorders. However, even when they examined sex-specific, age-adjusted rates by state, no correlation was identified between the geographic distribution of Lyme disease and any of the four neurodegenerative disorders. This finding suggests that differences in the distribution of the sexes by state did not affect the lack of correlation that was observed.
In conclusion, although associations between Lyme disease and Alzheimer disease, ALS, MS, and Parkinson disease have been proposed by writers of speculative websites and articles, supportive evidence for such an association is lacking. The absence of a positive correlation in the geographic distributions of these conditions provides further evidence against an association between Lyme disease and deaths from these four neurodegenerative conditions.
See the CDC Report
See also Medical Law Perspectives, November 2015 Report: Risks in Caring for Patients with Cognitive Impairments: Alzheimer’s Disease and Dementia
See also Medical Law Perspectives, April 2014 Report: Danger and Controversy: Lyme Disease Liability Risks
See the Medical Law Perspectives July 27, 2015, Blog: Problems of Proving a Lyme Disease Diagnosis